AB0243 CYSTEINE RICH 61 (CYR61): A POTENTIAL BIOMARKER ASSOCIATED WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS. (June 2019)

• Record Type: Journal Article
• Authors: Fan, Yong; Yang, Xinlei; Zhao, Juan; Sun, Xiaoying; Xie, Wenhui; Huang, Yanrong; Guangtao, LI; Hao, Yanjie; Zhang, Zhuoli
• Is Part Of: Annals of the rheumatic diseases. Volume 78(2019)Supplement 2
• Page Start: 1578
• Page End: 1578
• Publication Date: 2019-06
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2019-eular.5222
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Numerous preclinical studies have revealed a critical role of Cysteine rich 61 (Cyr61) in the pathogenesis of rheumatoid arthritis (RA). However, little is known about the potential value of circulation Cyr61 in clinical RA patients. Objectives: To compare serum Cyr61 level in patients with RA and healthy controls, and to characterize the potential association between Cyr61 and RA disease activity. Methods: In training cohort, serum samples were obtained from 177 patients with definite RA and 50 age- and gender- matched healthy controls. Medical records were collected and serum Cyr61 concentration was detected by enzyme-linked immunosorbent assay. Correlations between Cyr61 levels with clinical disease activity were analyzed. Furthermore, a validation cohort consisting of 77 active RA patients who received uniform biologic therapy for 12 weeks was set up (ClinicalTrials.gov identifier: NCT02320630 ). Paired serum samples were collected at baseline and after 12-week treatment for each individual and prepared for detection of Cyr61. Comparisons between groups were made using Mann-Whitney U test or Wilcoxon matched-pairs signed rank test, as appropriate. Results: Significant elevation of serum Cyr61 concentration was found in RA patients, demonstrating excellent diagnostic ability to discriminate RA with healthy controls (area under the curve (AUC) = 0.98, P < 0.001). In training cohort, Cyr61 level in active RA patients was significantly lower than that in inactive RA, and it was inversely with measures of clinical disease activity in statistic. Findings were further confirmed in our validation cohort. Active RA patients who had a reduction in disease activity showed a significantly increase of Cyr61 level after effective treatment (in terms of achieving ACR20/50/70 improvement criteria). RA patients who did not achieve ACR response showed no significant difference of Cyr61 level before and after treatment. Multivariate logistic regression analysis revealed that increase of Cyr61 level as well as younger age were independent indicators for achieving ACR20 response. Conclusion: Serum Cyr61 levels were remarkably increased in RA patients compared with healthy control. More intriguingly, the level of Cyr61 was inversely associated with RA disease activity and increased after effective treatment. References: [1] Zhang Q, Wu J, Cao Q, Xiao L, Wang L, He D, et al. A critical role of Cyr61 in interleukin-17-dependent proliferation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis & Rheumatism. 2009;60(12):3602-12. [2] Chen CY, Su CM, Hsu CJ, Huang CC, Wang SW, Liu SC, et al. CCN1 Promotes VEGF Production in Osteoblasts and Induces Endothelial Progenitor Cell Angiogenesis by Inhibiting miR-126 Expression in Rheumatoid Arthritis. J BONE MINER RES. 2017 2017-01-01;32(1):34-45. [3] Barranco C. CCN1, a novel RA target? NAT REV RHEUMATOL. 2016 2016-08-19;12(10):561. Conflict of interest: The authors declare that they have no competing interests. Disclosure of Interests: None declared